Price (delayed)
$82.03
Market cap
$18.86B
P/E Ratio
21.64
Dividend/share
N/A
EPS
$3.79
Enterprise value
$19.78B
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise
There are no recent dividends present for HZNP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.